Recurrent urinary tract infections (rUTI) represent a significant public health burden, contributing to substantial healthcare costs, impaired quality of life, and increasing antimicrobial resistance. The gastrointestinal tract serves as a key reservoir for uropathogenic organisms. Modulation of the gut microbiome may influence UTI susceptibility. Fecal microbiota transplantation (FMT) is an established and highly effective therapy for recurrent, treatment-refractory Clostridioides difficile colitis. Emerging evidence has suggested a potential role for FMT in reducing rUTI frequency by depleting pathogenic bacterial reservoirs and promoting recolonization with commensal organisms associated with more favorable antimicrobial resistance profiles.
We performed a retrospective cohort study of women who underwent FMT for C difficile colitis between 2010 and 2025 at a single institution. Patients with a concomitant diagnosis of rUTI, defined by American Urological Association (AUA) guidelines, were included. The primary outcome was the number of symptomatic, culture-proven UTIs occurring within the two-year periods before and after FMT. Secondary outcomes included changes in antimicrobial resistance patterns, including the presence of vancomycin-resistant Enterococcus (VRE) on urine culture.
Ten patients with a mean age of 70.1 years (range 51 – 95) met inclusion criteria. Subjects averaged 5.8 UTIs (range 2 – 19) in the two years prior to FMT. Following FMT, mean UTI frequency decreased to 1.5 (range 0 – 5) over the same time period (p = 0.01265). Notably, three patients had VRE identified on pre-FMT urine cultures; none demonstrated VRE on post-FMT cultures.
FMT was associated with a statistically significant reduction in rUTI frequency and elimination of VRE on subsequent urine cultures in female patients. Modulation of the gut microbiome may play a meaningful role in the prevention of rUTIs.
Our findings support the utilization of FMT for the treatment of rUTIs in women. Prospective clinical trials using microbiome-targeted therapies are warranted to further evaluate the efficacy and durability of FMT as a strategy for rUTI management.